Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
teprotumumab insulin-like growth factor i receptor NA Successful target TTD , DGIDB Disorder of eye[MeSHID:D005128]
Thyroid Gland[MeSHID:D013961]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Macular Edema
Cystoid[MeSHID:D008269]
Graves Disease[MeSHID:D006111]		 1.68 approved antagonist
teprotumumab insulin-like growth factor 1 receptor biotech NA drugbank , DGIDB Disorder of eye[MeSHID:D005128]
Thyroid Gland[MeSHID:D013961]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Macular Edema
Cystoid[MeSHID:D008269]
Graves Disease[MeSHID:D006111]		 1.68 approved,investigational binder,antibody
teprotumumab insulin-like growth factor i receptor NA Successful target TTD , DGIDB Disorder of eye[MeSHID:D005128]
Thyroid Gland[MeSHID:D013961]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Macular Edema
Cystoid[MeSHID:D008269]
Graves Disease[MeSHID:D006111]		 1.68 approved antibody
teprotumumab insulin-like growth factor 1 receptor biotech NA drugbank , DGIDB Disorder of eye[MeSHID:D005128]
Thyroid Gland[MeSHID:D013961]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Macular Edema
Cystoid[MeSHID:D008269]
Graves Disease[MeSHID:D006111]		 1.68 approved,investigational binder,antibody,antagonist
click here to return to the previous page